Roche vaults in­to lead in front­line triple neg­a­tive breast can­cer as Tecen­triq/Abrax­ane com­bo aces pro­gres­sion-free sur­vival

Fast on the heels of a key suc­cess for small cell lung can­cer, Roche’s Tecen­triq team at Genen­tech has scored an­oth­er front­line win for the phar­ma gi­ant.

This time the in­ves­ti­ga­tors say that Tecen­triq com­bined with Cel­gene’s Abrax­ane sig­nif­i­cant­ly im­proved pro­gres­sion-free sur­vival in triple neg­a­tive breast can­cer — a first in the field.

We don’t know the da­ta, which are be­ing held for a fu­ture con­fer­ence. But the suc­cess here puts Roche at the goal line with ap­pli­ca­tions be­ing read­ied for the FDA and the EMA — with a high per­cent­age shot at suc­cess.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER